



ASX Announcement

30 March 2026

Atomo Completes Capital Raise

- **Atomo to raise up to \$4.0 million via placement and share purchase plan.**

SYDNEY, Australia, 30 March 2026 - Atomo Diagnostics Limited (ASX: AT1) (the “**Company**”) announces that it has completed a Share Placement to institutional and sophisticated professional investors with a Share Purchase Plan to follow.

CAPITAL RAISE

The Company is undertaking a capital raising to raise up to \$4.0 million, by way of a placement to raise \$3.0 million (“**Placement**”) and a Share Purchase Plan (“**SPP**”) to raise up to \$1.0 million (together known as “**Capital Raising**”). The Company has received binding commitments for \$3.0 million under the Placement.

The Placement will result in the issuance of approximately 90.9 million new fully paid ordinary shares (“**Shares**”) at an issue price of \$0.033 (3.3 cents) per share with 45.5 million free attaching options, exercisable at \$0.045 (4.5 cents) expiring 2.5 years from the date of issue, on the basis of one option for every two new shares subscribed for and issued (“**Options**”). The issue price of \$0.033 represents a ~10% discount to the 15-day VWAP of \$0.0368.

All new Shares and attaching Options will be issued under the Company’s ASX L.R. 7.1 and 7.1A placement capacity.

The Company is pleased to confirm that the net proceeds of the Capital Raising in conjunction with pro forma cash on hand of ~\$3.5m as at 31 December 2025 will fund the Company through to early 2028¹.

The use of funds for the Capital Raising is to expand commercialisation of Atomo’s own portfolio of proprietary diagnostic tests, including Active Syphilis and Liver function, deliver operational scale up to support increased demand for supply of Pascal cassettes for Lumos’ FebriDx growth in the US and working capital alongside costs of the Capital Raising.

¹ The SPP is not underwritten.



Placement

The Company has received binding commitments for the purchase to issue Placement Shares and Options to institutional and sophisticated professional investors under section 708 of the Corporations Act 2001 (Cth) as follows:

- 9,891,563 Placement Shares and 45,454,040 Options under the Company's existing Placement Capacity under ASX Listing Rule 7.1; and
- 81,017,528 Placement Shares under the Company's existing Placement Capacity under ASX Listing Rule 7.1A.

The Placement was undertaken by the Company with Joint Lead Managers Alpine Capital Pty Ltd and GBA Capital Pty Ltd ("**JLM's**"). The JLM's will receive a 6% broker fee on all funds raised in addition to 5 million Broker Options to be issued on the same terms as the Placement and SPP free attaching options. Bay Financial Pty Ltd acted as Co-Manager.

Share Purchase Plan

In addition to the Placement, the Company will also offer eligible shareholders with a registered address in Australia or New Zealand the opportunity to participate in a share purchase plan ("**SPP**") for up to \$1.0 million in new fully paid ordinary shares ("**SPP Shares**") at the same issue price as the Placement with one free attaching New Option for every two SPP Share subscribed for and issued ("**SPP Securities**"). Eligibility for the SPP was determined at 7:00pm on Friday, 27 March 2026.

Eligible shareholders will be entitled to apply for up to A\$30,000 worth of SPP Shares, targeting an SPP raise of up to \$1 million before costs. Full details of the SPP, including any scale back of applications in the event of oversubscriptions, will be contained in the SPP Prospectus which is expected to be despatched on or around Thursday, 16 April 2026. The issuance of SPP Securities will be issued out of the Company's existing placement capacity under ASX Listing Rule 7.1.

New shares issued under the Capital Raising will rank equally with the shares already on issue. The Company will apply for quotation for the Placement Shares and SPP Shares (subject to the conditions of the ASX Listing Rules), with the Options (both free attaching and Broker) remaining unlisted.

For personal use only



TIMETABLE

The intended timetable for the Placement and SPP is as follows:

Event	Date
Record date for SPP	7:00pm on Friday, 27 March 2026
Capital Raising announced and trading halt lifted	Monday, 30 March 2026
Settlement of Placement Securities	Thursday, 2 April 2026
Allotment of Placement Securities	Tuesday, 7 April 2026
Despatch Prospectus and SPP Open Date	Thursday, 16 April 2026
SPP Close Date	Friday, 8 May 2026
Announcement of SPP Results	Wednesday, 13 May 2026
Allotment of SPP Offer Securities	Friday, 15 May 2026

**The above timetable is indicative only and subject to change. The quotation of new shares is subject to ASX approval. Subject to the ASX Listing Rules and Corporations Act and other applicable laws, the Company reserves the right to vary these dates, without notice. Any extension of the SPP will have a consequential effect on the issue date of the new shares.*

Managing Director John Kelly said *"To support anticipated growth in the business, we are pleased to have secured firm commitments from institutional and sophisticated professional investors to raise approximately \$3.0 million through the Placement and thank them for their support. We are also delighted to extend the opportunity to all our existing shareholders on the same terms as the Placement through the SPP".* Mr Kelly added, *"This additional capital enables the company to expand commercialisation of Atomo's own portfolio of proprietary diagnostic tests, including Active Syphilis and Liver function, deliver operational scale up to support increased demand for supply of Pascal cassettes for Lumos' FebriDx growth in the US, new "Atomo inside" customers and Atomo's own products."*

For more information, please contact:
John Kelly
Atomo Diagnostics
john.kelly@atomodiagnostics.com
Phone: +61 401 922 279

This announcement was authorised by the Board of Directors of Atomo Diagnostics Limited.

For personal use only



About Atomo

Atomo is an Australian headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of test products across international markets and has supply agreements in place for testing applications targeting infectious diseases including HIV, Active Syphilis, Liver function, viral vs bacterial differentiation, as well as the early detection of pregnancy.

See more at www.atomodiagnosics.com

For personal use only